Πηγαίνετε σε ένα σημείο του ευρετηρίου:
Αποτελέσματα 1 έως 9 από 9
ΤύποςΗμερομηνίαΤίτλοςΔημιουργόςΠλήρες κείμενο
Text
2008Sensitivity to TRAIL induced apoptosis in vivo via DR5 receptor up-regulation and the role of oncogenesOikonomou, E.; Kosmidou, V.; Katseli, A.; Taoufik, E.; Lesley, P.; Zografos, G.; Andera, L.; Pintzas, Alexander
Metadata only
Text
2009Presence of K-RAS and BRAF oncogenic mutations sensitise colorectal tumours to TRAIL induced apoptosis: evidence from cell and animal models translated to the clinicPintzas, Alexander; Oikonomou, E.; Andera, L.; Zografos, G.; Kontogeorgos, G.; Kosmidou, V.
Metadata only
Text
2009TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumorsOikonomou, Eftychia; Kosmidou, Vivian; Katseli, Anastasia; Kothonidis, Konstantinos; Mourtzoukou, Despina; Kontogeorgos, George; Andera, Ladislav; Zografos, Georgios; Pintzas, Alexander
Restricted access
Text
2010RAS and BRAF oncogenes sensitise colorectal tumours to TRAIL induced apoptosis: from cell and animal models to the clinicPintzas, Alexander; Oikonomou, E.; Andera, L.; Zografos, G.; Kontogeorgos, G.; Kosmidou, V.
Metadata only
Text
2011Trail induced cell death in colon carcinoma cells in vivo and in vitro: Sensitization by oncogenes and by other therapeuticsOikonomou, E.; Psahoulia, F.; Kosmidou, V.; Taoufik, E.; Probert, L.; Andera, L.; Pintzas, Alexander
Metadata only
Text
2013EZH2 is regulated by ERK/AKT and targets integrin alpha2 gene to control Epithelial-Mesenchymal Transition and anoikis in colon cancer cellsFerraro A.; Mourtzoukou D.; Kosmidou V.; Avlonitis S.; Kontogeorgos G.; Zografos G.; Pintzas A.
Metadata only
Text
2014Epigenetic regulation of miR-21 in colorectal cancer: ITGB4 as a novel miR-21 target and a three-gene network (miR-21-ITGB44-PCDC4) as predictor of metastatic tumor potentialFerraro A.; Kontos C.K.; Boni T.; Bantounas I.; Siakouli D.; Kosmidou V.; Vlassi M.; Spyridakis Y.; Tsipras I.; Zografos G.; Pintzas A.
Metadata only
Text
2014Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implicationsKosmidou V.; Oikonomou E.; Vlassi M.; Avlonitis S.; Katseli A.; Tsipras I.; Mourtzoukou D.; Kontogeorgos G.; Zografos G.; Pintzas A.
Metadata only
Text
2016Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancerDevetzi M.; Kosmidou V.; Vlassi M.; Perysinakis I.; Aggeli C.; Choreftaki T.; Zografos G.N.; Pintzas A.
Metadata only